Literature DB >> 9186817

Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.

E Arvat1, B Maccagno, J Ramunni, L Gianotti, L Di Vito, R Deghenghi, F Camanni, E Ghigo.   

Abstract

The role of histamine in the neural control of GH secretion in man is still unclear, although a stimulatory influence has been hypothesized in man. To clarify this point, in 7 normal young women (23-28 yr) in their early follicular phase, we studied the effect of the histaminergic blockade by diphenhydramine (DPH, 80 mg os at -60 min) on the GH response to GHRH (2 micrograms/Hg iv) or Hexarelin (HEX, 2 micrograms/kg iv), a synthetic hexapeptide with strong GH-releasing effect. In 6 of the 7 women the effect of terfenadine (TRF, 120 mg os at -60 min), another H1-receptor antagonist, on the GH response to GHRH or HEX was also studied. As HEX has also PRL- and ACTH-releasing activity and histamine has been shown to have a stimulatory role in the neural control of these hormones, the effects of DPH or TRF on the HEX-induced PRL. ACTH and cortisol release were also studied. GHRH induced a GH rise (peak, mean +/- SEM: 35.4 +/- 6.5 vs 2.5 +/- 1.1 micrograms/l, p < 0.02, n = 7; 34.7 +/- 7.9 vs 3.9 +/- 1.5 micrograms/l, p < 0.02, n = 6) lower (p < 0.05) than that elicited by HEX (49.1 +/- 8.5 vs 3.9 +/- 1.0 micrograms/l, p < 0.01, n = 7; 48.7 +/- 8.9 vs 3.2 +/- 0.8 micrograms/l, p < 0.01, n = 6). DPH inhibited the GH response to both GHRH (AUC: 453.9 +/- 104.7 vs 1223.7 +/- 202.6 micrograms*min/l, p < 0.05) and HEX (922.0 +/- 215.4 vs 1636.4 +/- 267.5 micrograms*min/l, p < 0.05), although the HEX-induced GH rise persisted higher than that induced by GHRH (p < 0.05). TRF did not modify the GHRH-induced GH rise (950.5 +/- 369.2 mg*min/l vs 1115.3 +/- 255.6 micrograms*min/l) as well as the somatotrope responsiveness to HEX (1163.2 +/- 188.7 vs 1427.3 +/- 323.3 mg*min/l). HEX also significantly increased PRL (13.9 +/- 3.1 vs 6.5 +/- 0.8 micrograms/l, p < 0.03), ACTH (31.1 +/- 6.6 vs 16.6 +/- 2.9 pg/ml, p < 0.02) and cortisol (96.6 +/- 6.3 vs 82.2 +/- 6.2 micrograms/L, p < 0.05) levels. PRL, ACTH and cortisol responses to HEX were unaffected by DPH (536.5 +/- 85.6 vs 599.5 +/- 129.2 micrograms*min/l, 1068.5 +/- 306.0 vs 1282.8 +/- 222.0 pg*min/ml and 4277.4 +/- 588.4 vs 4738.3 +/- 355.3 micrograms*min/l, respectively) as well as by TRF (621.3 +/- 110.4 vs 530.3 +/- 131.4 micrograms*min/L, 972.4 +/- 189.6 vs 1060.2 +/- 224.7 pg*min/ml and 6203.8 +/- 1329.5 vs 5141.2 +/- 295.5 micrograms*min/l, respectively). In conclusion, our findings are against the hypothesis of a major role of H1-receptor-mediated histaminergic influence on GH secretion in humans. In fact, the H1-histaminergic blockade by TRF does not affect the GH response to GHRH or HEX; the inhibitory effect of DPH may probably be due to its intrinsic anticholinergic activity. Our data also confirm that Hexarelin releases more GH than GHRH and demonstrate that its effect on GH, PRL and ACTH release is not mediated by H1-receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186817     DOI: 10.1007/BF03346889

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Effect of meclastine, a selective H1 receptor antagonist, upon ACTH release.

Authors:  B Allolio; U Deuss; D Kaulen; W Winkelmann
Journal:  Clin Endocrinol (Oxf)       Date:  1983-08       Impact factor: 3.478

2.  Effect of the antihistaminic agents meclastine and dexchlorpheniramine on the response of human growth hormone to arginine infusion and insulin hypoglycemia.

Authors:  A E Pontiroli; G Viberti; A Vicari; G Pozza
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

Review 3.  Physiology of growth hormone secretion and action.

Authors:  F F Casanueva
Journal:  Endocrinol Metab Clin North Am       Date:  1992-09       Impact factor: 4.741

4.  Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.

Authors:  M Maccario; E Arvat; M Procopio; L Gianotti; S Grottoli; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1995-01       Impact factor: 8.694

5.  Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

Authors:  E Ghigo; E Arvat; L Gianotti; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

6.  Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles.

Authors:  T Jacks; G Hickey; F Judith; J Taylor; H Chen; D Krupa; W Feeney; W Schoen; D Ok; M Fisher
Journal:  J Endocrinol       Date:  1994-11       Impact factor: 4.286

7.  Modulation of growth hormone-releasing activity of hexarelin in man.

Authors:  E Arvat; L Gianotti; L Di Vito; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni; E Ghigo
Journal:  Neuroendocrinology       Date:  1995-01       Impact factor: 4.914

8.  Comparative effect of cimetidine and ranitidine on prolactin secretion.

Authors:  G F Nelis; J G Van de Meene
Journal:  Postgrad Med J       Date:  1980-07       Impact factor: 2.401

9.  Effects of cimetidine on pituitary function: Alterations in hormone secretion profiles.

Authors:  T W Valk; B G England; J C Marshall
Journal:  Clin Endocrinol (Oxf)       Date:  1981-08       Impact factor: 3.478

10.  Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33-824 in man.

Authors:  A Peñalva; L Villanueva; F Casanueva; F Cavagnini; A Gomez-Pan; E E Müller
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more
  4 in total

1.  The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.

Authors:  J Bellone; S Bellone; G Aimaretti; M R Valetto; C Baffoni; G Corneli; C Origlia; E Arvat; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

2.  Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.

Authors:  E Arvat; J Ramunni; R Giordano; B Maccagno; F Broglio; A Benso; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

3.  Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Authors:  E Arvat; L Di Vito; F Lanfranco; F Broglio; R Giordano; A Benso; G P Muccioli; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

Review 4.  Biologic activities of growth hormone secretagogues in humans.

Authors:  E Ghigo; E Arvat; R Giordano; F Broglio; L Gianotti; M Maccario; G Bisi; A Graziani; M Papotti; G Muccioli; R Deghenghi; F Camanni
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.